Esperite NV (ESP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
44
About the Report
About the Report
Summary
Esperite NV (Esperite) formerly Cryo-Save Group N.V. is a stem cell storage company. It collects, processes and stores human adult stem cells obtained from umbilical cord blood and cord tissue. The company holds expertise in proteomic and genomic predictive medicine; and cryopreservation of human adult stem cells. Esperite also offers next generation sequencing services including genomic diagnostics, bioinformatics and cytogenetic analysis by utilizing next generation sequencing platforms such as SOLiD, GAII, HiSeq and MiSeq, among others. The company operates a research and development division, the Cell Factory, which is involved in developing advanced cell therapy medicinal products and new therapies in the field of regenerative medicine. Esperite is headquartered in Zutphen, Gelderland, the Netherlands.
Esperite NV (ESP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Esperite NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperite NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperite NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperite NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Esperite NV, Medical Devices Deals, 2012 to YTD 2018 10
Esperite NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Esperite NV, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Cryo-Save Completes Acquisition Of Assets From Salveo Biotech For USD2.8 Million 12
Private Equity 14
Cryo-Save Completes Management Buyout Of Cryo-Save (India) 14
Equity Offering 15
Esperite Announces Private Placement of Shares for USD1.3 Million 15
Esperite Raises Funds through IPO 16
Debt Offering 17
Esperite to Raise up to USD5.8 Million in Private Placement of Notes 17
Esperite Raises USD0.6 Million in Nineteenth Tranche of Private Placement of Notes 18
Esperite Raises USD0.5 Million in Eighteenth Tranche of Private Placement of Notes 20
Esperite to Raise USD0.5 Million in seventeenth Tranche of Private Placement of Notes 22
Esperite Raises USD0.3 Million in Sixteenth Tranche of Private Placement of Notes 24
Esperite Raises USD0.3 Million in Fourteenth Tranche of Private Placement of Notes 26
Esperite Raises USD0.3 Million in Thirteenth Tranche of Private Placement of Notes 27
Esperite Raises USD0.3 Million in Eleventh Tranche of Private Placement of Notes 28
Esperite Raises USD0.7 Million in Additional Tranches of Private Placement of Notes 29
Esperite Raises USD1.2 Million in Additional Tranches of Private Placement of Notes Due 2018 30
Esperite Raises USD1 Million in First Tranche of Private Placement of Notes Due 2018 31
Asset Transactions 32
Cryo-Save Completes Acquisition Of Assets From Salveo Biotech For USD2.8 Million 32
Esperite NV-Key Competitors 33
Esperite NV-Key Employees 34
Esperite NV-Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 37
Financial Announcements 37
Oct 02, 2017: ESPERITE publishes its half-year report 37
May 31, 2017: ESPERITE Q1 consolidated revenue higher compared to budget 38
May 23, 2017: Esperite Financial Results For 2016 Published 39
Legal and Regulatory 40
May 19, 2017: Esperite announces that Genoma filed appeal to the decision ruled by the Swiss Court 40
Product News 41
Apr 25, 2017: Esperite With Cryosave Contributes To Treating A 9 Year Old Child With Thalassemia Major In Switzerland 41
Other Significant Developments 42
Sep 13, 2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva 42
Jan 10, 2018: ESPERITE transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List of Figure
List of Figures
Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Esperite NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Esperite NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Esperite NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperite NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Esperite NV, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Esperite NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperite NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperite NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperite NV, Deals By Therapy Area, 2012 to YTD 2018 9
Esperite NV, Medical Devices Deals, 2012 to YTD 2018 10
Esperite NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cryo-Save Completes Acquisition Of Assets From Salveo Biotech For USD2.8 Million 12
Cryo-Save Completes Management Buyout Of Cryo-Save (India) 14
Esperite Announces Private Placement of Shares for USD1.3 Million 15
Esperite Raises Funds through IPO 16
Esperite to Raise up to USD5.8 Million in Private Placement of Notes 17
Esperite Raises USD0.6 Million in Nineteenth Tranche of Private Placement of Notes 18
Esperite Raises USD0.5 Million in Eighteenth Tranche of Private Placement of Notes 20
Esperite to Raise USD0.5 Million in seventeenth Tranche of Private Placement of Notes 22
Esperite Raises USD0.3 Million in Sixteenth Tranche of Private Placement of Notes 24
Esperite Raises USD0.3 Million in Fourteenth Tranche of Private Placement of Notes 26
Esperite Raises USD0.3 Million in Thirteenth Tranche of Private Placement of Notes 27
Esperite Raises USD0.3 Million in Eleventh Tranche of Private Placement of Notes 28
Esperite Raises USD0.7 Million in Additional Tranches of Private Placement of Notes 29
Esperite Raises USD1.2 Million in Additional Tranches of Private Placement of Notes Due 2018 30
Esperite Raises USD1 Million in First Tranche of Private Placement of Notes Due 2018 31
Cryo-Save Completes Acquisition Of Assets From Salveo Biotech For USD2.8 Million 32
Esperite NV, Key Competitors 33
Esperite NV, Key Employees 34
Esperite NV, Subsidiaries 35
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.